Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
about
The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer TherapyTwenty years of anti-HER2 therapy-associated cardiotoxicityCreating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer PatientsCuring Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of CardiologyBreast cancer therapy-associated cardiovascular disease.Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts.Arterial stiffness in hematologic malignancies.Pharmacogenetics of anthracyclines.Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy.Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.Mangifera indica L. leaf extract alleviates doxorubicin induced cardiac stress.Chemotherapy-induced cardiotoxicity: importance of early detection.Chemotherapeutic-Induced Cardiovascular Dysfunction: Physiological Effects, Early Detection-The Role of Telomerase to Counteract Mitochondrial Defects and Oxidative Stress.Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy.Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment.Toxicity and Safety Evaluation of Doxorubicin-Loaded Cockleshell-Derived Calcium Carbonate Nanoparticle in Dogs
P2860
Q26743433-DD85E4D9-FF1E-4E46-AE1A-B83777464AE7Q28079391-B9B3065E-586A-4BD7-92E0-C938F0F2C8B8Q33816471-9CDE8D57-5D83-4077-91BD-E7D0542CB555Q35997676-493465ED-4F77-48D9-9BED-0A3470EB42D2Q37052852-50C9F02B-4A6E-45C8-856B-03E80056BBCBQ38645182-AE125C4C-48DF-4A1A-A189-1105C5A5522CQ38657849-5790536D-CBEA-403D-9FF2-00B9DCEBA23CQ38829602-B5D9D506-7CEA-4F98-AEC3-4F77639205A6Q38856218-B874EB85-F38A-4AD4-8B6D-E1E91645A961Q39018351-38E8BEFA-ADE7-401B-A3BA-F042D30D70C0Q39164190-1A55E652-B9B3-4DF9-B74D-0019B9673C07Q39344380-D3E0C5C2-2481-4D5B-8DDF-31840422A8BBQ50068205-830FA13F-0410-4C2C-8F1F-5ED4AA7932ADQ50144200-E973800F-B38B-4A79-A73D-FD5BD5A7EB64Q53748861-FCFD8013-C5BD-4E3A-8738-5B4952ABBDEAQ54959206-ED4E831C-942C-45EA-9E31-0A2CE6B5C277Q54976923-B77169EB-7936-4879-87A6-35DF55EE460BQ55429574-951FF32E-D9A9-44F3-A107-8A5CD1C19552Q57213890-FE2C027A-2B37-4A28-BF6E-B1E7F219D574
P2860
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity
@nl
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
@ast
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
@en
type
label
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity
@nl
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
@ast
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
@en
prefLabel
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity
@nl
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
@ast
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
@en
P2093
P2860
P3181
P1476
Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.
@en
P2093
Ben H Park
Eric S Christenson
Theodore James
Vineet Agrawal
P2860
P304
P3181
P356
10.1016/J.CLINBIOCHEM.2014.10.013
P407
P577
2014-11-07T00:00:00Z